Ambry Genetics announced today the launch of BRCA1 and BRCA2 analysis as part of their comprehensive cancer-testing menu. Two genes will be offered as a stand alone test comprising of full gene sequencing and deletion/duplication analyses in addition to being incorporated as part of multiple hereditary cancer panels that test cancer susceptibility genes using next-generation sequencing (NGS) technology. Additionally, Ambry Genetics is excited to launch a new high-risk hereditary breast cancer panel (BRCAplus) that simultaneously analyzes six clinically actionable genes: BRCA1, BRCA2, CDH1, PTEN, STK11 and TP53. These additions complement Ambry's comprehensive menu of single gene offerings and NGS multi-gene panels designed for hereditary cancer syndromes.
“With the launch of BRCA1/2 genetic testing, Ambry Genetics now offers the most comprehensive suite of hereditary cancer testing available”
Ambry Genetics is a CLIA-certified service laboratory specializing in clinical diagnostic and genomic services with a comprehensive menu of over 300 tests that has offered NGS-based gene panel testing since 2009. Incorporating BRCA1/2 genes allows Ambry to expand its testing for hereditary cancer syndromes and thus provide patients with more comprehensive cancer screening tests.
BRCA1/2 are tumor suppressor genes that have an essential role in both DNA repair and cell cycle control systems. BRCA1/2 germline mutations are inherited in an autosomal dominant pattern. When mutated, the genetic alterations affect DNA repair leading to increased lifetime risk to develop multiple cancers. Germ-line BRCA1/2 mutations are implicated in majority of hereditary breast-ovarian cancer syndrome (HBOC) cases. In these cases, women carrying a BRCA1/2 mutation have between a 40-80% lifetime risk to develop breast cancer and between a 20-40% lifetime risk to develop ovarian cancer. Male BRCA mutation carriers have up to a 30-39% lifetime risk for prostate and a 5-10% lifetime risk for male breast cancer. Cancer risks are further modified by family history, reproductive choices, lifestyle and environmental factors and other genetic factors.
"With the launch of BRCA1/2 genetic testing, Ambry Genetics now offers the most comprehensive suite of hereditary cancer testing available," said Charles Dunlop, Chief Executive Officer of Ambry Genetics. "Ambry's BRCA1/2 testing includes gene sequence and deletion/duplication analyses at a competitively lower cost and comparable turn-around time to the laboratory that previously controlled BRCA1/2 analysis."
Ambry Genetics fully supports awareness and the need for cancer screening of individuals with a personal or family history of inherited cancer syndromes like HBOC. While hereditary breast and ovarian cancer accounts for 5-10% of all breast and ovarian cancer cases, approximately 25-50% of these are due to BRCA1/2 mutation. BRCA1/2 carrier frequency is estimated at 1/400 or 0.2% in the non-Ashkenazi Jewish (AJ) population. Mutations in the BRCA genes are much more common in individuals of AJ descent, with a carrier frequency of 1/40 or 2.6%. Establishing a molecular diagnosis of HBOC then becomes crucial, as it can help guide preventative measures, direct surgical options and estimate personal and familial cancer risk.
"The relationship between BRCA1/2 and breast cancer risk was not discovered by a single patent holder, it stood on the shoulders of years of work by our scientific colleagues. Ambry is a beneficiary of these collaborative efforts of the research community both in US and worldwide. We have access to tremendous resources for the classification of BRCA1/2 variants and accurate association with cancer risk," said Elizabeth Chao, M.D., Chief Medical Officer at Ambry Genetics. "This provides us with a strong basis for a variant classification program that will be second to none."